CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 75 enrolled
Drug / intervention
mNavigatorother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03677128
NCT03677128N/ACompleted
CompareCT.gov

A Mobile Health (mHealth) Case Management System for Reducing Pediatric Cancer Treatment Abandonment

Duke University·interventional·Posted Sep 19, 2018·Updated May 9, 2023

In Brief

A clinical study evaluating mNavigator for Burkitt Lymphoma and 2 related conditions. Completed, enrolled 75 participants across 1 site.

Detailed Summary

Digital case management systems have the potential to increase compliance with protocol-driven treatment, reduce treatment abandonment and ultimately help to close the discrepancy in pediatric cancer outcomes between Low and Middle Income Countries (LMICs) and high-income countries (HICs). The investigators aim to adapt an open-source digital case management platform to incorporate standardized pediatric oncology protocols. Effectiveness will be evaluated by provider protocol compliance (primary outcome) and patient treatment abandonment rates using the digital case management system as compared to historic controls. The study population will include patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma (DLBCL) or retinoblastoma at Bugando Medical Centre in Tanzania.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBurkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma
CountriesTanzania
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 19, 2018
Enrollment StartJul 23, 2019
Primary CompletionApr 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.8 years ago

Interventions

mNavigatorother

Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.